Choose a language and wait for the translated text.
The U.S. Food and Drug Administration in April proposed withdrawing the drug, which treats a rare autoimmune disease that damages blood vessels, citing a lack of proven effectiveness and false statements in its original marketing application.
Amgen submits new data to challenge FDA's proposal to withdraw Tavneos | PharmaVoice
